This page was translated automatically from Turkish. Read the original

This page is an AI-assisted Turkish summary of the study presented at the 26th World Congress of Psychiatry. The study belongs to the presenting authors; please refer to the original source when citing it.

Substance use disorder and co-occurring attention-deficit/hyperactivity disorder: results of the International Naturalistic Cohort Study of ADHD and Substance Use Disorders (INCAS)

Substance use disorder (sud) and co-morbid attention deficit/hyperactivity disorder (adhd): results from the international naturalistic cohort study of adhd and sud (incas)

Among adults with substance use disorder and co-occurring ADHD, ADHD treatment was significantly associated with better treatment retention, reduced ADHD symptoms, and fewer heavy drinking days at three months.

The study aimed to identify predictors of treatment outcomes in adults with co-occurring attention-deficit/hyperactivity disorder (ADHD) and substance use disorder (SUD). In this international, multicenter, observational, prospective cohort study, data were collected at baseline, week four, month three, and month nine at twelve treatment centers in nine countries between June 2017 and May 2021. The primary outcomes were treatment retention, a reduction of at least 30% from baseline on the Adult ADHD Self-Report Scale (ASRS-18), and self-reported substance use at three months; the study enrolled 137 women (24%) and 441 men (76%). Receiving stimulant treatment for ADHD was significantly associated with better treatment retention at three months (odds ratio, OR: 2.4; 95% confidence interval, CI: 1.4–4.2), a reduction of at least 30% in the total ASRS score (OR: 2.6; 95% CI: 1.2–6.1), and fewer heavy drinking days (incidence rate ratio, IRR: 0.24; 95% CI: 0.13–0.42). Psychosocial treatment for ADHD was also independently and significantly associated with fewer heavy drinking days at three months (IRR: 0.27; 95% CI: 0.14–0.51). The findings highlight the importance of providing ADHD treatment in this population; the authors note that randomized controlled trials (RCTs) evaluating combinations of ADHD and SUD treatments with different stimulant doses are needed to confirm the results.

All WCP 2026 summaries